Fig. 1From: A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center studyKaplan-Meier estimate for the time to relapse (a) and time to disease activity (failure to achieve NEDA-3 status) (b). In b, the curve drop at 12 months is mainly related to detection of disease activity by brain MRI scansBack to article page